Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Operating Margin: 2012-2025

Historic Operating Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to 1.43%.

  • Ptc Therapeutics' Operating Margin rose 2913.00% to 1.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.61%, marking a year-over-year increase of 5837.00%. This contributed to the annual value of -37.50% for FY2024, which is 936.00% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Operating Margin stood at 1.43%, which was up 107.31% from -19.54% recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Operating Margin high stood at 82.50% for Q1 2025, and its period low was -119.67% during Q4 2022.
  • Over the past 3 years, Ptc Therapeutics' median Operating Margin value was -24.67% (recorded in 2024), while the average stood at -27.07%.
  • As far as peak fluctuations go, Ptc Therapeutics' Operating Margin soared by 16,449bps in 2021, and later tumbled by 7,807bps in 2024.
  • Over the past 5 years, Ptc Therapeutics' Operating Margin (Quarterly) stood at -51.28% in 2021, then tumbled by 6,839bps to -119.67% in 2022, then soared by 12,156bps to 1.90% in 2023, then plummeted by 7,807bps to -76.18% in 2024, then skyrocketed by 2,913bps to 1.43% in 2025.
  • Its last three reported values are 1.43% in Q3 2025, -19.54% for Q2 2025, and 82.50% during Q1 2025.